trending Market Intelligence /marketintelligence/en/news-insights/trending/uic-uHsgfdxUMOcvF-hgrw2 content esgSubNav
In This List

Kaleido BioSciences seeking up to $100M in Nasdaq IPO

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Kaleido BioSciences seeking up to $100M in Nasdaq IPO

Kaleido BioSciences Inc. is planning to raise up to $100 million in an IPO on Nasdaq.

The Lexington, Mass.-based biotechnology company, whose pipeline includes medicines for infections caused by drug-resistant bacteria, heart and kidney diseases, and diarrhea, plans to list its shares on the Nasdaq Global Select Market under the symbol KLDO.

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Canaccord Genuity LLC are the underwriters of the IPO and will have an option to buy additional shares in the offering.